Key result
Stachydrine suppressed platelet activation and reduced susceptibility to thrombosis and sepsis-induced multiorgan damage in mouse models.
Why the study?
The significance of stachydrine in platelet regulation and whether it could ameliorate platelet-mediated thrombo-inflammation remained elusive.
Does Stachydrine reduce thrombosis and thrombo-inflammation in preclinical mouse models?
Does Stachydrine reduce thrombosis and thrombo-inflammation in preclinical mouse models?
Stachydrine exhibits novel antiplatelet properties that reduce thrombosis and thrombo-inflammation in preclinical models.
Stachydrine merits investigation as an antiplatelet agent in sepsis; leaves open translation from mouse models to human thrombosis and thrombo-inflammation.
BACKGROUND: Platelets are versatile anucleate cells involved in thrombosis as well as inflammation. Stachydrine (STA), a major bioactive compound extracted from Motherwort, has multiple pharmacological properties. Nevertheless, the significance of STA in platelet regulation and whether STA could ameliorate platelet-mediated thrombo-inflammation still remain elusive. METHODS: injury-induced carotid/mesenteric thrombosis and collagen/epinephrine-induced pulmonary thromboembolism model were used to explore whether STA could regulate thrombosis in vivo. Furthermore, a cecal ligation and puncture-induced sepsis model was employed to investigate the role of STA in thrombo-inflammatory diseases. RESULTS: STA markedly suppressed platelet activation represented by aggregation, secretion, αIIbβ3-mediated signaling events and calcium mobilization, etc. by inhibiting agonists-induced activation signaling and potentiating cGMP-dependent inhibitory signaling. Mice receiving STA-treated platelets were less susceptible to thrombosis in vivo. In addition, decreased platelet-neutrophil interactions including platelet-neutrophil aggregates and neutrophil extracellular traps, and alleviative sepsis-induced multiorgan damage were observed due to STA-mediated platelet inhibition. CONCLUSION: This study suggested the potential therapeutic role of STA in thrombotic and thrombo-inflammatory disorders.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2022) studied Thrombosis and thrombo-inflammation. Stachydrine was evaluated on Platelet activation, thrombosis, and sepsis-induced multiorgan damage. Stachydrine suppressed platelet activation and reduced susceptibility to thrombosis and sepsis-induced multiorgan damage in mouse models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: